ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC

By 2024 ESMO Annual Meeting Insights Hub FEATURING Giuseppe Viale

10 views

September 23, 2024

0 Comments

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo

12:14

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

Feat. P. Tarantino

11:31

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino

12:35

Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo

07:23

Total Health

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Feat. R. O'Regan

03:40

Integrity CE

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & …

Feat. A. Bardia

14:16

Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino

10:53

Kirollos Hanna

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

09:55

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton

17:39

Yale School of Medicine

2023 Menopause Update

Feat. M. Minkin

09:19

Insights from 2023 SABCS

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for…

Feat. K. Kalinsky

05:43

Total Health

Neoadjuvant Chemo for HR+ BC: Year in Review

Feat. C. Ma

17:20

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino

27:01

Scripps Health

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Feat. S. Sammons

57:44

Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl

36:18

Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Feat. H. Rugo

22:34

Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney

10:34

Sara Tolaney

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Feat. H. Rugo

33:44

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive &a…

Feat. S. Tolaney, H. Rugo

16:19

Wassim Mchayleh

Login

Login

Join VuMedi

ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC

Related Content